Sanofi-Aventis, the French drug giant that has labs in Cambridge, MA, said today that it paid Dana Farber Cancer Institute of Boston $33 million to license technology for identifying cancer targets for new treatments. Dana Farber will also receive research funding from Sanofi for a minimum of three years, as well as potential payments related to the development of drugs that result from the agreement. In July, Sanofi revealed that it planned to house a new cancer research division in Cambridge and invest $65 million in expanding its operations there.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
